Creative BioMolecules/Stryker
This article was originally published in The Gray Sheet
Executive Summary
Creative BioMolecules completes the sale of OP-1 morphogenic protein assets and manufacturing rights to Stryker. The deal, a definitive agreement for which was announced Oct. 16 ("The Gray Sheet" Oct. 19, p. 11), "significantly enhances" CBM's near term cash flow with the receipt of approximately $20 mil. and "the elimination of commercial manufacturing-related expenses and capital investments," the company says